Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00115492
Status:
COMPLETED
Last Update Posted:
2017-01-20
First Post:
2005-06-22
Brief Title:
Advair DISKUS Versus Serevent DISKUS For Chronic Obstructive Pulmonary Disease Exacerbations
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Double-Blind Parallel Group 52-Week Study to Compare the Effect of Fluticasone PropionateSalmeterol Diskus Combination Product 25050mcg BID With Salmeterol Diskus 50mcg BID on the Annual Rate of ModerateSevere Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the effect of two medicines on COPD Chronic Obstructive Pulmonary Disease exacerbations This study will last up to 56 weeks and subjects will visit the clinic 10 times Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards All study related medicines and medical examinations will be provided at no cost The two drugs used in this study have been approved by FDA for use in patients with COPD
Detailed Description:
A Randomized Double-Blind Parallel Group 52-week Study to Compare the Effect of the Fluticasone PropionateSalmeterol DISKUS Combination Product 25050mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of ModerateSevere Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease COPD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None